Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Impax Laboratories Inc    IPXL

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Impax Laboratories Inc : Impax Laboratories to Present at the UBS Global Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/20/2013 | 01:35pm CEST

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 a.m. Eastern Standard Time. The conference will be held at the Sheraton New York Hotel.

Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at www.impaxlabs.com. This presentation will be archived on the Company's web site for 30 days.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.

Impax Laboratories, Inc.
Mark Donohue, 215-558-4526
Investor Relations and Corporate Communications
www.impaxlabs.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMPAX LABORATORIES INC
05/17 IMPAX LABORATORIES, INC. (NASDAQ : IPXL) Files An 8-K Submission of Matters to a..
05/17 IMPAX LABORATORIES INC : Submission of Matters to a Vote of Security Holders (fo..
05/17 IMPAX LABORATORIES : to Present at the UBS Global Healthcare Conference
05/16 IMPAX LABORATORIES : Bisaro to cut first and buy later as he works to restore Im..
05/11 IMPAX LABORATORIES : to Present at the Bank of America Merrill Lynch Healthcare ..
05/10 IMPAX LABORATORIES : Management's Discussion and Analysis of Results of Operatio..
05/10 IMPAX LABORATORIES INC (NASDAQ : IPXL) reported earnings of $0.11 per share miss..
05/10 IMPAX LABORATORIES INC : Investor Network: Impax Laboratories, Inc. to Host Earn..
05/10 IMPAX LABORATORIES, INC. (NASDAQ : IPXL) Files An 8-K Results of Operations and ..
05/10 IMPAX LABORATORIES INC : Results of Operations and Financial Condition, Regulati..
More news
Sector news : Pharmaceuticals - NEC
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- 2nd Updat..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/12 After Hours Gainers / Losers
05/10 Impax Laboratories (IPXL) Q1 2017 Results - Earnings Call Transcript
05/10 Impax Laboratories, Inc. 2017 Q1 - Results - Earnings Call Slides
05/10 PREMARKET GAINERS AS OF 9 : 05 am
05/10 Impax Lab misses by $0.02, misses on revenue
Advertisement
Financials ($)
Sales 2017 789 M
EBIT 2017 99,0 M
Net income 2017 -76,0 M
Debt 2017 443 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 23,25
EV / Sales 2017 2,04x
EV / Sales 2018 1,93x
Capitalization 1 168 M
More Financials
Chart IMPAX LABORATORIES INC
Duration : Period :
Impax Laboratories Inc Technical Analysis Chart | IPXL | US45256B1017 | 4-Traders
Full-screen chart
Technical analysis trends IMPAX LABORATORIE...
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 15,5 $
Spread / Average Target -2,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Paul M. Bisaro President, Chief Executive Officer & Director
Robert L. Burr Chairman
Andrew Schaschl Senior Vice President-Global Operations
Bryan M. Reasons Chief Financial Officer & Senior VP-Finance
Jeffrey D. Nornhold Senior Vice President-Technical Operations
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMPAX LABORATORIES INC19.25%1 168
JOHNSON & JOHNSON10.68%343 545
ROCHE HOLDING LTD.14.88%236 038
NOVARTIS AG6.68%212 104
PFIZER INC.-1.32%191 517
MERCK & CO., INC.10.48%177 895
More Results